FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938682102> ?p ?o ?g. }

• W2938682102 endingPage "30" @default.
• W2938682102 startingPage "30" @default.
• W2938682102 abstract "OBJECTIVES/SPECIFIC AIMS: Peripheral neuropathy is the dose limiting toxicity of paclitaxel treatment. Paclitaxel pharmacokinetics (PK), specifically the Cmax and amount of time the concentration remains above 0.05 µM (Tc>0.05), have been associated with occurrence of severe, clinician-documented neuropathy. The objective of this study was to confirm that paclitaxel PK predicts progression of patient-reported neuropathy. METHODS/STUDY POPULATION: This observational trial enrolled breast cancer patients receiving weekly 1-hour paclitaxel infusions (80 mg/m 2 ×12 cycles) at the University of Michigan Comprehensive Cancer Center. Paclitaxel concentration was measured via LC/MS in plasma samples collected at the end of (Cmax) and 16–24 hours after (Tc>0.05) first infusion. Patient-reported neuropathy was collected (EORTC CIPN20) at baseline and each cycle. The rate of neuropathy severity increase per treatment cycle is being modeled for each patient. Cmax and Tc>0.05 values will be introduced into the model to confirm that PK independently contributes to neuropathy progression. RESULTS/ANTICIPATED RESULTS: PK and neuropathy data have been collected from 60 patients for ongoing analysis. Our initial model will characterize the expected severity of neuropathy after each cycle of paclitaxel treatment. The PK-neuropathy model will include either PK parameter to validate their contribution to the progression of neuropathy severity during treatment. We anticipate, based on our preliminary analysis of the first 16 patients, that both PK parameters will significantly contribute to the model but Tc>0.05 will be more strongly associated with neuropathy progression. DISCUSSION/SIGNIFICANCE OF IMPACT: This project will generate a model that can be used to predict a patient’s neuropathy severity throughout treatment using a single, conveniently collected and easily measured PK sample during their first cycle. The next steps of this project include identifying genetic and metabolomic biomarkers that predict which patients experienced more severe neuropathy than would be anticipated based on their paclitaxel PK, and a planned interventional trial of personalized paclitaxel dosing to enhance efficacy and/or prevent neuropathy." @default.
• W2938682102 created "2019-04-25" @default.
• W2938682102 creator A5060814135 @default.
• W2938682102 creator A5062446153 @default.
• W2938682102 creator A5069778809 @default.
• W2938682102 creator A5070047430 @default.
• W2938682102 creator A5075359631 @default.
• W2938682102 date "2017-09-01" @default.
• W2938682102 modified "2023-09-27" @default.
• W2938682102 title "2043" @default.
• W2938682102 doi "https://doi.org/10.1017/cts.2017.114" @default.
• W2938682102 hasPublicationYear "2017" @default.
• W2938682102 type Work @default.
• W2938682102 sameAs 2938682102 @default.
• W2938682102 citedByCount "0" @default.
• W2938682102 crossrefType "journal-article" @default.
• W2938682102 hasAuthorship W2938682102A5060814135 @default.
• W2938682102 hasAuthorship W2938682102A5062446153 @default.
• W2938682102 hasAuthorship W2938682102A5069778809 @default.
• W2938682102 hasAuthorship W2938682102A5070047430 @default.
• W2938682102 hasAuthorship W2938682102A5075359631 @default.
• W2938682102 hasBestOaLocation W29386821021 @default.
• W2938682102 hasConcept C112705442 @default.
• W2938682102 hasConcept C121608353 @default.
• W2938682102 hasConcept C126322002 @default.
• W2938682102 hasConcept C134018914 @default.
• W2938682102 hasConcept C143998085 @default.
• W2938682102 hasConcept C22979827 @default.
• W2938682102 hasConcept C2777292972 @default.
• W2938682102 hasConcept C2779901536 @default.
• W2938682102 hasConcept C2908647359 @default.
• W2938682102 hasConcept C555293320 @default.
• W2938682102 hasConcept C71924100 @default.
• W2938682102 hasConcept C90924648 @default.
• W2938682102 hasConcept C99454951 @default.
• W2938682102 hasConceptScore W2938682102C112705442 @default.
• W2938682102 hasConceptScore W2938682102C121608353 @default.
• W2938682102 hasConceptScore W2938682102C126322002 @default.
• W2938682102 hasConceptScore W2938682102C134018914 @default.
• W2938682102 hasConceptScore W2938682102C143998085 @default.
• W2938682102 hasConceptScore W2938682102C22979827 @default.
• W2938682102 hasConceptScore W2938682102C2777292972 @default.
• W2938682102 hasConceptScore W2938682102C2779901536 @default.
• W2938682102 hasConceptScore W2938682102C2908647359 @default.
• W2938682102 hasConceptScore W2938682102C555293320 @default.
• W2938682102 hasConceptScore W2938682102C71924100 @default.
• W2938682102 hasConceptScore W2938682102C90924648 @default.
• W2938682102 hasConceptScore W2938682102C99454951 @default.
• W2938682102 hasIssue "S1" @default.
• W2938682102 hasLocation W29386821021 @default.
• W2938682102 hasLocation W29386821022 @default.
• W2938682102 hasOpenAccess W2938682102 @default.
• W2938682102 hasPrimaryLocation W29386821021 @default.
• W2938682102 hasRelatedWork W1856793902 @default.
• W2938682102 hasRelatedWork W1964941112 @default.
• W2938682102 hasRelatedWork W1982777678 @default.
• W2938682102 hasRelatedWork W2145658083 @default.
• W2938682102 hasRelatedWork W2304647222 @default.
• W2938682102 hasRelatedWork W2373411783 @default.
• W2938682102 hasRelatedWork W2437346096 @default.
• W2938682102 hasRelatedWork W2552418679 @default.
• W2938682102 hasRelatedWork W2902366943 @default.
• W2938682102 hasRelatedWork W4213286047 @default.
• W2938682102 hasVolume "1" @default.
• W2938682102 isParatext "false" @default.
• W2938682102 isRetracted "false" @default.
• W2938682102 magId "2938682102" @default.
• W2938682102 workType "article" @default.